COVID Protocols Literature Grid
Report abuse
Use this data
Sign up for free
Title
1
COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids.
2
RV Infections in Asthmatics Increase ACE2 Expression and Cytokine Pathways Implicated in COVID-19.
3
COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?
4
Symptoms and Critical Illness Among Obstetric Patients With Coronavirus Disease 2019 (COVID-19) Infection.
5
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
6
COVID-19–related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids
7
COVID-19–related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids
8
Effect of Asthma and Asthma Medication on the Prognosis of Patients with COVID-19.
9
COVID-19 Susceptibility in Bronchial Asthma
10
COVID-19-related genes in sputum cells in asthma: relationship to demographic features and corticosteroids
11
Is asthma protective against COVID‐19?
12
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Drag to adjust the number of frozen columns
Author
Journal
Publication Date
DOI Link
Brief Summary
Abstract
Section
Topic
Level of Evidence
Journal Impact Factor
Key literature?
Peters MC, Sajuthi S, Deford P, et al
American Journal of Respiratory and Critical Care Medicine
7/1/2020
doi.org/10.1164/rccm.202003-0821OC

Rationale: Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmembrane protease serine 2) mediate viral infection of host cells. We reasoned that differences in ACE2 or TMPRSS2 gene expression in sputum cells among patients with asthma may identify subgroups at risk for COVID-19 morbidity.

Therapeutics
Respiratory
Health Equity
Systemic Corticosteroids
Baseline Lung Disease
Asthma
Racial Disparities
ACE2
15.303
Chang EH, Willis AL, Romanoski CE, Cusanovich DA, Pouladi N, Li J, Lussier YA, Martinez FD
American Journal of Respiratory and Critical Care Medicine
7/1/2020
doi.org/10.1164/rccm.202004-1343LE


Respiratory
Pathology
Asthma
ACE2
Baseline Lung Disease
Respiratory Viral Coinfection and Influenza
15.303
Maes T, Bracke K, Brusselle GG
American Journal of Respiratory and Critical Care Medicine
7/1/2020
doi.org/10.1164/rccm.202005-1651ED
Authors examined ACE2 mRNA expression in lung tissue of patients with asthma, COPD, or healthy controls (all white). COPD was associated with increased ACE2 expression but in patients with obstructive airway disease, inhaled corticosteroids were not associated with significant changes in ACE2 receptor expression.

Maes T, Bracke K, Brusselle GG

Clinical Course
Therapeutics
Inhaled Corticosteroids
Asthma
Baseline Lung Disease
Level 4- Uncontrolled Cohort, Case Series, Consensus Panel
15.303
Andrikopoulou M, Madden N, Wen T, Aubey JJ, Aziz A, Baptiste CD, Breslin N, DʼAlton ME, Fuchs KM, Goffman D, Gyamfi-Bannerman C, Matseoane-Peterssen DN, Miller RS, Sheen JJ, Simpson LL, Sutton D, Zork N, Friedman AM
Obstetrics and gynecology
8/1/2020
doi.org/10.1097/AOG.0000000000003996
In this cohort of 158 women at 2 hospitals in NY, about 1/5 had moderate or severe disease. Comorbid conditions such as asthma were more common among women with moderate and severe disease, of whom a proportion required admission (15/34), oxygen supplementation/support (10/15) and ICU or step-down level of care (9/15)

OBJECTIVE: To characterize symptoms and disease severity among pregnant women with coronavirus disease 2019 (COVID-19) infection, along with laboratory findings, imaging, and clinical outcomes. METHODS: Pregnant women with COVID-19 infection were identified at two affiliated hospitals in New York City from March 13 to April 19, 2020, for this case series study. Women were diagnosed with COVID-19 infection based on either universal testing on admission or testing because of COVID-19-related sympt

Obstetrics
Clinical Course
Respiratory
Severity and Prognostic Indicators
Baseline Lung Disease
Asthma
Level 3- Case Control, Retrospective Cohort, Systematic Review
5.618
Jin-Jin Zhang, Xiang Dong, Yi-Yuan Cao, Ya-Dong Yuan, Yi-Bin Yang, You-Qin Yan, Cezmi A Akdis, Ya-Dong Gao
Allergy
2/27/2020
doi.org/10.1111/all.14238

Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been widely spread. We aim to investigate the clinical characteristic and allergy status of patients infected with SARS-CoV-2.

Clinical Course
Respiratory
Baseline Lung Disease
Asthma
COPD
Comorbidity
Severity and Prognostic Indicators
7.466
Michael C. Peters, Satria Sajuthi, Peter Deford, Stephanie Christenson, Cydney L. Rios, Michael T. Montgomery, Prescott G. Woodruff, David T. Mauger, Serpil C. Erzurum, Mats W. Johansson, Loren C. Denlinger, Nizar N. Jarjour, Mario Castro, Annette T. Hastie, Wendy Moore, Victor E. Ortega, Eugene R. Bleecker, Sally E. Wenzel, Elliot Israel, Bruce D. Levy, Max A. Seibold, and John V. Fahy; on behalf of the NHLBI Severe Asthma Research Program-3 Investigators
American Journal of Respiratory and Critical Care Medicine
doi.org/10.1164/rccm.202003-0821OC
Banked cells from sputum samples in patients with asthma or healthy controls were analyzed for expression of known SARS-CoV2 receptors, ACE2 and TMPRSS2. Notable findings include (a) increased receptor expression in men, patients who identify as African American and patients with diabetes, and (b) decreased receptor expression in patients with a personal history of inhaled corticosteroid use. The authors postulate these results may provide mechanistic insight into COVID-19 outcomes in these sub

Rationale: Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 (angiotensin- converting enzyme 2), and TMPRSS2 (transmembrane protease serine 2) mediate viral infection of host cells. We reasoned that differences in ACE2 or TMPRSS2 gene expression in sputum cells among patients with asthma may identify subgroups at risk for COVID-19 morbidity.

Epidemiology
Health Equity
Asthma
Comorbidity
Inhaled Corticosteroids
Racial Disparities
Level 1- Homogenous Metanalyses or RCTs
15.303
Michael C. Peters, Satria Sajuthi, Peter Deford, Stephanie Christenson, Cydney L. Rios, Michael T. Montgomery, Prescott G. Woodruff, David T. Mauger, Serpil C. Erzurum, Mats W. Johansson, Loren C. Denlinger, Nizar N. Jarjour, Mario Castro, Annette T. Hastie, Wendy Moore, Victor E. Ortega, Eugene R. Bleecker, Sally E. Wenzel, Elliot Israel, Bruce D. Levy, Max A. Seibold, and John V. Fahy; on behalf of the NHLBI Severe Asthma Research Program-3 Investigators
American Journal of Respiratory and Critical Care Medicine
7/1/2020
doi.org/10.1164/rccm.202003-0821OC
Authors examined cellular RNA expression of SARS-CoV2 receptors in induced-sputum samples from patients with asthma and healthy controls. Expression of the ACE2 and TMPSS2 receptors in airway cells was similar in patients with asthma compared to healthy controls. In the cohort of patients with asthma, ICS use was associated with decreased ACE2 receptor expression. Factors that were associated with increased receptor expression included self-reported male sex, African-American race and diabetes

Rationale: Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmembrane protease serine 2) mediate viral infection of host cells. We reasoned that differences in ACE2 or TMPRSS2 gene expression in sputum cells among patients with asthma may identify subgroups at risk for COVID-19 morbidity.

Clinical Course
Health Equity
ACE2
Severity and Prognostic Indicators
Asthma
Inhaled Corticosteroids
Level 3- Case Control, Retrospective Cohort, Systematic Review
15.303
Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, Cho JH, Kim HJ, Lee JH, Park JW, Park HJ
The European Respiratory Journal
9/1/2020
doi.org/10.1183/13993003.02226-2020

BACKGROUND: Coronavirus disease (COVID-19) has rapidly spread worldwide. However, the effects of asthma, asthma medication, and asthma severity on the clinical outcomes of COVID-19 have not yet been established.

Respiratory
Asthma
Level 3- Case Control, Retrospective Cohort, Systematic Review
11.706
Green et al.
The Journal of Allergy and Clinical Immunology: In Practice
11/24/2020
doi.org/10.1016/j.jaip.2020.11.020
Background
Respiratory
Asthma
Michael C. Peters et al.
Am J Respir Crit Care Med.
7/1/2020
doi.org/10.1164/rccm.202003-0821OC

Rationale: Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmembrane protease serine 2) mediate viral infection of host cells. We reasoned that differences in ACE2 or TMPRSS2 gene expression in sputum cells among patients with asthma may identify subgroups at risk for COVID-19 morbidity.Objectives: To determine the relationship between demographic features and sputum ACE2 and TMPRSS

Respiratory
Asthma
Carli et al.
European Journal of Allergy and Clinical Immunology
6/1/2020
doi.org/10.1111/all.14426
Respiratory
Asthma
Schultze et al.
The Lancet Respiratory Medicine
9/24/2020
doi.org/10.1016/S2213-2600(20)30415-X
Background
Respiratory
Therapeutics
COPD
Asthma
Inhaled Corticosteroids
12 records

Alert

Lorem ipsum
Okay